Literature DB >> 31086

Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.

J L Campra, T B Reynolds.   

Abstract

Ten patients with ascites due to chronic liver disease were treated with spironolactone as the sole diuretic in doses of 300 to 600 mg daily. Prior to spironolactone treatment ascites was relatively refractory as indicated by baseline 24-hr urine sodium values of less than 5 mEq and natriuresis of less than 30 mEq following 200 mg hydrochlorothiazide. With spironolactone, mean daily weight loss was 540 g and natriuresis 74 mEq; diuresis was considered satisfactory in nine of ten patients. Untoward effects were limited to a single episode of hepatic encephalopathy, a small fall in serum magnesium in several patients, and three instances of hyperkalemia (5.5, 5.6, and 7.5 mEq/liter). In spite of the tendency to hyperkalemia, urinary potassium excretion increased in seven of the ten patients. There was no rise in serum urea nitrogen or creatinine. Hydrogen ion excretion decreased initially leading to mild hyperchloremic acidosis. Serum urate did not increase.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 31086     DOI: 10.1007/bf01263103

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


  10 in total

1.  DIURETIC THERAPY. VII. SPIRONOLACTONE.

Authors:  M M SINGER; A C DEGRAFF
Journal:  Am Heart J       Date:  1964-12       Impact factor: 4.749

2.  SPIRONOLACTONE THERAPY AND GYNECOMASTIA.

Authors:  E CLARK
Journal:  JAMA       Date:  1965-07-12       Impact factor: 56.272

3.  Metabolic studies on the effects of sprinolacton.

Authors:  H JICK; R S MORRISON; E W MOORE; T C CHALMERS
Journal:  Metabolism       Date:  1963-05       Impact factor: 8.694

4.  A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.

Authors:  D A OGDEN; L SCHERR; N SPRITZ; A L RUBIN
Journal:  N Engl J Med       Date:  1961-08-24       Impact factor: 91.245

5.  An effect of spironolactone on urinary acidification in normal man.

Authors:  M A Manuel; G J Beirne; J P Wagnild; M W Weiner
Journal:  Arch Intern Med       Date:  1974-09

6.  Compartmentalization of ascites and edema in patients with hepatic cirrhosis.

Authors:  L Shear; S Ching; G J Gabuzda
Journal:  N Engl J Med       Date:  1970-06-18       Impact factor: 91.245

7.  Edema formation and the use of diuretics.

Authors: 
Journal:  Calif Med       Date:  1971-03

8.  The complications of diuretic therapy in patients with cirrhosis.

Authors:  S Sherlock; J G Walker; B Senewiratne; A Scott
Journal:  Ann N Y Acad Sci       Date:  1966-11-22       Impact factor: 5.691

9.  Spironolactone diuresis in patients with cirrhosis and ascites.

Authors:  R C Eggert
Journal:  Br Med J       Date:  1970-11-14

10.  High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.

Authors:  J P Radó; J Marosi; J Takó
Journal:  Endokrinologie       Date:  1970
  10 in total
  6 in total

1.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 2.  [Diuretic resistance of liver cirrhosis: pharmacologic treatment approaches].

Authors:  P Gross; A Wichmann; A Sieg
Journal:  Klin Wochenschr       Date:  1989-08-01

3.  The hepatorenal syndrome revisited.

Authors:  S P Wilkinson
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

4.  Treatment of ascites in patients with cirrhosis of the liver.

Authors:  V Arroyo; P Ginés; J Rodés
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

5.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 6.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.